請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/34629
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 郭明良 | |
dc.contributor.author | Wan-Ting Hsieh | en |
dc.contributor.author | 謝宛庭 | zh_TW |
dc.date.accessioned | 2021-06-13T06:19:14Z | - |
dc.date.available | 2016-10-07 | |
dc.date.copyright | 2011-10-07 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-07-25 | |
dc.identifier.citation | 1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Yamamoto J, Kosuge T, Takayama T, et al. Recurrence of hepatocellular carcinoma after surgery. Br J Surg 1996;83:1219-22. 3. Schwartz M. Liver transplantation for hepatocellular carcinoma. Gastroenterology 2004;127:S268-76. 4. Poon RT, Fan ST, Lo CM, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 2001;234:63-70. 5. Llovet JM, Sala M, Castells L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000;31:54-8. 6. Barbare JC, Bouche O, Bonnetain F, et al. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol 2005;23:4338-46. 7. Yang ZF, Poon RT, To J, Ho DW, Fan ST. The potential role of hypoxia inducible factor 1alpha in tumor progression after hypoxia and chemotherapy in hepatocellular carcinoma. Cancer Res 2004;64:5496-503. 8. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-71. 9. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76. 10. Okabe H, Satoh S, Kato T, et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 2001;61:2129-37. 11. Murakami Y, Yasuda T, Saigo K, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006;25:2537-45. 12. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28. 13. Feinberg AP. The epigenetics of cancer etiology. Semin Cancer Biol 2004;14:427-32. 14. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006;7:21-33. 15. Bird A. Perceptions of epigenetics. Nature 2007;447:396-8. 16. Glasspool RM, Teodoridis JM, Brown R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer 2006;94:1087-92. 17. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983;301:89-92. 18. Esteller M, Fraga MF, Guo M, et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 2001;10:3001-7. 19. Suter CM, Martin DI, Ward RL. Hypomethylation of L1 retrotransposons in colorectal cancer and adjacent normal tissue. Int J Colorectal Dis 2004;19:95-101. 20. Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003;300:455. 21. Ehrlich M. Cancer-linked DNA hypomethylation and its relationship to hypermethylation. Curr Top Microbiol Immunol 2006;310:251-74. 22. Wilson AS, Power BE, Molloy PL. DNA hypomethylation and human diseases. Biochim Biophys Acta 2007;1775:138-62. 23. Itano O, Ueda M, Kikuchi K, et al. Correlation of postoperative recurrence in hepatocellular carcinoma with demethylation of repetitive sequences. Oncogene 2002;21:789-97. 24. Widschwendter M, Jiang G, Woods C, et al. DNA hypomethylation and ovarian cancer biology. Cancer Res 2004;64:4472-80. 25. Robertson KD. DNA methylation, methyltransferases, and cancer. Oncogene 2001;20:3139-55. 26. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-9. 27. Fraga MF, Herranz M, Espada J, et al. A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors. Cancer Res 2004;64:5527-34. 28. Alaminos M, Davalos V, Cheung NK, Gerald WL, Esteller M. Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J Natl Cancer Inst 2004;96:1208-19. 29. Tang X, Khuri FR, Lee JJ, et al. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst 2000;92:1511-6. 30. Esteller M, Gonzalez S, Risques RA, et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001;19:299-304. 31. Roman-Gomez J, Jimenez-Velasco A, Agirre X, et al. Promoter hypermethylation and global hypomethylation are independent epigenetic events in lymphoid leukemogenesis with opposing effects on clinical outcome. Leukemia 2006;20:1445-8. 32. Pruitt K, Zinn RL, Ohm JE, et al. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet 2006;2:e40. 33. Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005;37:391-400. 34. Ballestar E, Paz MF, Valle L, et al. Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. Embo J 2003;22:6335-45. 35. Fahrner JA, Eguchi S, Herman JG, Baylin SB. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res 2002;62:7213-8. 36. Nguyen CT, Gonzales FA, Jones PA. Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation. Nucleic Acids Res 2001;29:4598-606. 37. Seligson DB, Horvath S, Shi T, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005;435:1262-6. 38. Park YS, Jin MY, Kim YJ, Yook JH, Kim BS, Jang SJ. The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma. Ann Surg Oncol 2008;15:1968-76. 39. Wei Y, Xia W, Zhang Z, et al. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog 2008;47:701-6. 40. Kondo Y, Shen L, Suzuki S, et al. Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol Res 2007;37:974-83. 41. Dong KB, Maksakova IA, Mohn F, et al. DNA methylation in ES cells requires the lysine methyltransferase G9a but not its catalytic activity. EMBO J 2008;27:2691-701. 42. Ikegami K, Iwatani M, Suzuki M, et al. Genome-wide and locus-specific DNA hypomethylation in G9a deficient mouse embryonic stem cells. Genes Cells 2007;12:1-11. 43. Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008;647:21-9. 44. Kirmizis A, Bartley SM, Farnham PJ. Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy. Mol Cancer Ther 2003;2:113-21. 45. Kassambara A, Klein B, Moreaux J. MMSET is overexpressed in cancers: link with tumor aggressiveness. Biochem Biophys Res Commun 2009;379:840-5. 46. Steeg PS. Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 2003;3:55-63. 47. Bryant RJ, Cross NA, Eaton CL, Hamdy FC, Cunliffe VT. EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate 2007;67:547-56. 48. Choi JH, Song YS, Yoon JS, Song KW, Lee YY. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer. APMIS 2010;118:196-202. 49. Min J, Zaslavsky A, Fedele G, et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med 2010. 50. Watanabe H, Soejima K, Yasuda H, et al. Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells. Cancer Cell Int 2008;8:15. 51. Kondo Y, Shen L, Ahmed S, et al. Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells. PLoS One 2008;3:e2037. 52. Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of epigenetics. Genes Dev 2009;23:781-3. 53. Bolos V, Peinado H, Perez-Moreno MA, Fraga MF, Esteller M, Cano A. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci 2003;116:499-511. 54. Peinado H, Ballestar E, Esteller M, Cano A. Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol 2004;24:306-19. 55. Varier RA, Timmers HT. Histone lysine methylation and demethylation pathways in cancer. Biochim Biophys Acta 2011;1815:75-89. 56. Manuyakorn A, Paulus R, Farrell J, et al. Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704. J Clin Oncol;28:1358-65. 57. Zhang Y, Reinberg D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev 2001;15:2343-60. 58. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97. 59. Pillai RS, Bhattacharyya SN, Filipowicz W. Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol 2007;17:118-26. 60. Bentwich I, Avniel A, Karov Y, et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet 2005;37:766-70. 61. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009;19:92-105. 62. Brennecke J, Hipfner DR, Stark A, Russell RB, Cohen SM. bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell 2003;113:25-36. 63. Cuellar TL, McManus MT. MicroRNAs and endocrine biology. J Endocrinol 2005;187:327-32. 64. Poy MN, Eliasson L, Krutzfeldt J, et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004;432:226-30. 65. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004;303:83-6. 66. Miska EA. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev 2005;15:563-8. 67. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69. 68. Zamore PD, Haley B. Ribo-gnome: the big world of small RNAs. Science 2005;309:1519-24. 69. Zhang L, Huang J, Yang N, et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A 2006;103:9136-41. 70. Karube Y, Tanaka H, Osada H, et al. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci 2005;96:111-5. 71. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007;39:673-7. 72. Yang N, Coukos G, Zhang L. MicroRNA epigenetic alterations in human cancer: one step forward in diagnosis and treatment. Int J Cancer 2008;122:963-8. 73. Saito Y, Jones PA. Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle 2006;5:2220-2. 74. Rouhi A, Mager DL, Humphries RK, Kuchenbauer F. MiRNAs, epigenetics, and cancer. Mamm Genome 2008;19:517-25. 75. Kim H, Kwon YM, Kim JS, et al. Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer. Cancer 2006;107:1042-9. 76. Fabbri M, Garzon R, Cimmino A, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A 2007;104:15805-10. 77. Tachibana M, Sugimoto K, Fukushima T, Shinkai Y. Set domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3. J Biol Chem 2001;276:25309-17. 78. Rice JC, Briggs SD, Ueberheide B, et al. Histone methyltransferases direct different degrees of methylation to define distinct chromatin domains. Mol Cell 2003;12:1591-8. 79. Sedgwick SG, Smerdon SJ. The ankyrin repeat: a diversity of interactions on a common structural framework. Trends Biochem Sci 1999;24:311-6. 80. Tachibana M, Sugimoto K, Nozaki M, et al. G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes Dev 2002;16:1779-91. 81. Chen MW, Hua KT, Kao HJ, et al. H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. Cancer Res 2010;70:7830-40. 82. Boulias K, Talianidis I. Functional role of G9a-induced histone methylation in small heterodimer partner-mediated transcriptional repression. Nucleic Acids Res 2004;32:6096-103. 83. Gyory I, Wu J, Fejer G, Seto E, Wright KL. PRDI-BF1 recruits the histone H3 methyltransferase G9a in transcriptional silencing. Nat Immunol 2004;5:299-308. 84. Nishio H, Walsh MJ. CCAAT displacement protein/cut homolog recruits G9a histone lysine methyltransferase to repress transcription. Proc Natl Acad Sci U S A 2004;101:11257-62. 85. Roopra A, Qazi R, Schoenike B, Daley TJ, Morrison JF. Localized domains of G9a-mediated histone methylation are required for silencing of neuronal genes. Mol Cell 2004;14:727-38. 86. Wozniak RJ, Klimecki WT, Lau SS, Feinstein Y, Futscher BW. 5-Aza-2'-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation. Oncogene 2007;26:77-90. 87. Feldman N, Gerson A, Fang J, et al. G9a-mediated irreversible epigenetic inactivation of Oct-3/4 during early embryogenesis. Nat Cell Biol 2006;8:188-94. 88. Smallwood A, Esteve PO, Pradhan S, Carey M. Functional cooperation between HP1 and DNMT1 mediates gene silencing. Genes Dev 2007;21:1169-78. 89. Esteve PO, Chin HG, Smallwood A, et al. Direct interaction between DNMT1 and G9a coordinates DNA and histone methylation during replication. Genes Dev 2006;20:3089-103. 90. Kondo Y, Kanzawa T, Sawaya R, Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 2005;5:726-34. 91. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-76. 92. Bursch W. The autophagosomal-lysosomal compartment in programmed cell death. Cell Death Differ 2001;8:569-81. 93. Ogier-Denis E, Codogno P. Autophagy: a barrier or an adaptive response to cancer. Biochim Biophys Acta 2003;1603:113-28. 94. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008;132:27-42. 95. Morselli E, Galluzzi L, Kepp O, et al. Anti- and pro-tumor functions of autophagy. Biochim Biophys Acta 2009;1793:1524-32. 96. Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat Rev Cancer 2007;7:961-7. 97. Rautou PE, Mansouri A, Lebrec D, Durand F, Valla D, Moreau R. Autophagy in liver diseases. J Hepatol 2010;53:1123-34. 98. Lu YS, Kashida Y, Kulp SK, et al. Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology 2007;46:1119-30. 99. Jenkins DE, Oei Y, Hornig YS, et al. Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. Clin Exp Metastasis 2003;20:733-44. 100. Takeuchi H, Kondo Y, Fujiwara K, et al. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res 2005;65:3336-46. 101. Gao M, Yeh PY, Lu YS, et al. OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma. Cancer Res 2008;68:9348-57. 102. Kubicek S, O'Sullivan RJ, August EM, et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell 2007;25:473-81. 103. Chang Y, Zhang X, Horton JR, et al. Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294. Nat Struct Mol Biol 2009;16:312-7. 104. Bhutia SK, Dash R, Das SK, et al. Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24. Cancer Res 2010;70:3667-76. 105. Kabeya Y, Mizushima N, Ueno T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000;19:5720-8. 106. Kondo Y, Kondo S. Autophagy and cancer therapy. Autophagy 2006;2:85-90. 107. Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. J Pathol 2010;221:3-12. 108. Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell 2010;140:313-26. 109. Wiznerowicz M, Trono D. Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J Virol 2003;77:8957-61. 110. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120:15-20. 111. Marson A, Levine SS, Cole MF, et al. Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. Cell 2008;134:521-33. 112. Huang S, He X. The role of microRNAs in liver cancer progression. Br J Cancer 2011;104:235-40. 113. Law PT, Wong N. Emerging roles of microRNA in the intracellular signaling networks of hepatocellular carcinoma. J Gastroenterol Hepatol 2011;26:437-49. 114. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human MicroRNA targets. PLoS Biol 2004;2:e363. 115. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90. 116. Miller TE, Ghoshal K, Ramaswamy B, et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 2008;283:29897-903. 117. Nasser MW, Datta J, Nuovo G, et al. Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem 2008;283:33394-405. 118. Herceg Z, Paliwal A. Epigenetic mechanisms in hepatocellular carcinoma: How environmental factors influence the epigenome. Mutat Res 2011;727:55-61. 119. Wong VW, Yu J, Cheng AS, et al. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer 2009;124:2766-70. 120. Padgett KA, Lan RY, Leung PC, et al. Primary biliary cirrhosis is associated with altered hepatic microRNA expression. J Autoimmun 2009;32:246-53. 121. Santos-Rosa H, Caldas C. Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer 2005;41:2381-402. 122. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 2006;6:846-56. 123. Burdach S, Plehm S, Unland R, et al. Epigenetic maintenance of stemness and malignancy in peripheral neuroectodermal tumors by EZH2. Cell Cycle 2009;8:1991-6. 124. Suva ML, Riggi N, Janiszewska M, et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res 2009;69:9211-8. 125. Huang J, Dorsey J, Chuikov S, et al. G9a and Glp methylate lysine 373 in the tumor suppressor p53. J Biol Chem 2010;285:9636-41. 126. Kondo Y, Kanai Y, Sakamoto M, Mizokami M, Ueda R, Hirohashi S. Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis--A comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma. Hepatology 2000;32:970-9. 127. Ding ZB, Shi YH, Zhou J, et al. Association of autophagy defect with a malignant phenotype and poor prognosis of hepatocellular carcinoma. Cancer Res 2008;68:9167-75. 128. Takamura A, Komatsu M, Hara T, et al. Autophagy-deficient mice develop multiple liver tumors. Genes Dev 2011;25:795-800. 129. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109. 130. Ou DL, Shen YC, Yu SL, et al. Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res 2010;70:9309-18. 131. Chen KF, Chen HL, Tai WT, et al. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther 2011;337:155-61. 132. Chen H, Yan Y, Davidson TL, Shinkai Y, Costa M. Hypoxic stress induces dimethylated histone H3 lysine 9 through histone methyltransferase G9a in mammalian cells. Cancer Res 2006;66:9009-16. 133. Kerr TA, Korenblat KM, Davidson NO. MicroRNAs and liver disease. Transl Res 2011;157:241-52. 134. Zheng F, Liao YJ, Cai MY, et al. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut 2011. 135. Lakner AM, Bonkovsky HL, Schrum LW. microRNAs: Fad or future of liver disease. World J Gastroenterol 2011;17:2536-42. 136. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009;28:3526-36. 137. Bai S, Nasser MW, Wang B, et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem 2009;284:32015-27. 138. Kanai Y, Ushijima S, Tsuda H, Sakamoto M, Sugimura T, Hirohashi S. Aberrant DNA methylation on chromosome 16 is an early event in hepatocarcinogenesis. Jpn J Cancer Res 1996;87:1210-7. 139. Rajput S, Wilber A. Roles of inflammation in cancer initiation, progression, and metastasis. Front Biosci (Schol Ed) 2010;2:176-83. 140. Braconi C, Huang N, Patel T. MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology 2010;51:881-90. 141. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009;139:693-706. 142. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 2010;39:493-506. 143. Wu F, Zikusoka M, Trindade A, et al. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha. Gastroenterology 2008;135:1624-35 e24. 144. Loffler D, Brocke-Heidrich K, Pfeifer G, et al. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 2007;110:1330-3. 145. Schetter AJ, Nguyen GH, Bowman ED, et al. Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin Cancer Res 2009;15:5878-87. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/34629 | - |
dc.description.abstract | 不正常的後遺傳調控 (epigenetic regulation) 時常導致疾病發生,包括癌症。癌細胞普遍呈現出不正常的DNA 甲基化 (methylation) 模式、組蛋白修飾 (histone modification),以及非編碼RNA (non-coding RNA) 的表現。G9a 為哺乳動物的組蛋白甲基轉移酶,負責催化組蛋白H3 上第九個離胺酸 (K9) 的甲基化,組蛋白H3K9 的甲基化對腫瘤抑制基因轉錄的抑制扮演關鍵性的角色。已知在缺氧的情形下,會誘發G9a 表現及增加其甲基轉移酶活性進而調控基因表現。我們先前研究發現,在肺癌和卵巢癌的腫瘤組織,G9a 的表現程度高的患者其預後較差,並參與在轉移及侵襲過程中的分子調控。除此之外,過去研究指出,G9a mRNA 亦高度表現在肝癌病人的腫瘤組織中,但是目前對於其扮演的角色仍不清楚。因此,我們試圖探討G9a 在肝癌發展過程中的重要性及其調控機轉。在本研究論文中,我們發現相較於腫瘤周邊正常組織,G9a 高度表現在肝癌病人的腫瘤組織中,顯示其可能參與調控腫瘤的生成。利用特異性G9a 抑制劑BIX-01294 阻斷其組蛋白甲基轉移酶活性以及在G9a 高度表現之細胞株利用小片段干擾核醣核酸 (siRNA) 抑制G9a 表現,皆觀察到癌細胞存活率下降之情形,進一步探究原因發現,抑制G9a的癌細胞生長抑制與細胞自噬 (autophagy) 作用有關,同時偵測到ATG4 表現量上升,顯示G9a 可能藉由此分子途徑調控細胞自噬。動物實驗結果也證明,在持續表現siRNA 抑制 G9a 表現的肝癌細胞株可以顯著減緩腫瘤生長,並且可能透過誘發腫瘤的細胞自噬及抑制腫瘤血管新生來達成。另外,在對於多重激酶抑制劑sorafenib 具有抗性之肝癌細胞株中發現,G9a 表現量和生長速度均較親代細胞大幅增加,顯示出G9a 在癌細胞抗藥性發展過程中扮演重要角色。為了釐清G9a 所受調控情形,我們分析了可能調控G9a 的微型核糖核酸 (microRNA),其中特異表現於肝臟之miR-122 可直接結合到G9a mRNA 的3’非轉譯區 (3’UTR) 並抑制G9a的表現。先前的證據顯示,慢性發炎和癌症進程之間的關連性,我們進而處理發炎反應相關的細胞激素IL-6 可誘發G9a 蛋白表現量增加,顯示G9a 的表現與發炎以及腫瘤微環境有所關聯。綜合以上研究,顯示G9a 在肝癌發展過程中扮演重要角色,未來有機會運用在抗藥性癌症的治療上。 | zh_TW |
dc.description.abstract | Aberrations of epigenetic regulation influence many diseases involving in cancer.Cancer epigenetics have shown extensive reprogramming of every component of the epigenetic machinery in cancer including DNA methylation, histone modifications,
nucleosome positioning and non-coding RNAs, specifically microRNA expression. G9a is a major mammalian H3K9 methyltransferase that contributes to the epigenetic silencing of tumor suppressor gene. It has been reported that hypoxia induced G9a protein expression and enzyme activity which leads to diverse transcriptional regulation of downstream functional genes. In our previous studies, elevated levels of G9a were correlated with poor prognosis in lung and ovarian cancer, and act as a regulator of genes involved in invasion and metastasis. In addition, it has been proposed that the mRNA expression of G9a in hepatocellular carcinoma (HCC) was higher than non-tumor tissue statistically, however, its functional and biological roles in HCC remains unclear. Hence, in this study we attempt to explore the functional roles of G9a and its possible regulatory mechanisms during HCC cancer progression. Here, we also found that G9a mRNA expression is up-regulated in HCC than non-cancerous liver tissue. These results indicate that G9a seems to be required for HCC carcinogenesis. Using specific G9a inhibitor – BIX-01294 or RNAi-mediated knockdown of G9a in HCC cells with higher endogenous G9a expression inhibited cell proliferation in vitro and tumor growth in vivo by induction of autophagy-associated cell death which is associated with up-regulation of ATG4. On the other hand, we observed that G9a protein up-regulated in sorafenib-resistant HCC cell line, knockdown of G9a in sorafenib-resistant HCC cell line abrogated this phenomenon. This finding indicates that high G9a protein level might lead to growth advantage of HCC cells under inhospitable condition and contribute to the development of drug-resistant cancer cells. To further understand the regulation of G9a up-regulation during cancer progression, we analyzed miRNA that can regulate the expression of G9a. miR-122, an liver-specific miRNA, can direct bind to 3’-UTR of G9a mRNA and thereby suppress G9a protein expression. As the evidence linking chronic inflammation to cancer progression, we found that treatment of inflammatory cytokine – IL-6 can induce the protein expression of G9a,indicating that regulation of G9a might correlate with inflammatory and tumor microenvironments. Together, G9a plays a crucial role during HCC cancer progression and might act as a therapeutic molecular target of drug-resistant cancer cells in the near future. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T06:19:14Z (GMT). No. of bitstreams: 1 ntu-100-R98447004-1.pdf: 4471792 bytes, checksum: 50c725da31d3e73f0a44228924dea83a (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 中文摘要 i
Abstract ii Chapter 1. Introduction 1 1.1 An overview of hepatocellular carcinoma (HCC) 1 1.2 Epigenetic regulation and cancer progression 2 1.3 Mechanism of epigenetic modification 5 1.4 The functions of G9a 10 1.5 Autophagy in cancer development 12 1.6 Hypothesis 15 Chapter 2. Materials and Methods 16 Chapter 3. Results 21 3.1 G9a is overexpressed in tumor tissue from hepatocellular carcinoma (HCC) patients 21 3.2 Inhibition of G9a enzyme activity by BIX-01294 results in cell growth inhibition through autophagy-associated cell death in human HCC cells 21 3.3 Knockdown of G9a causes cell growth defects in HCC cells 22 3.4 Knockdown of G9a induces autophagy 23 3.5 Knockdown of G9a retards tumor growth in vivo by using an orthotopic model of HCC 23 3.6 Knockdown of G9a led to up-regulation of ATG4 24 3.7 Downregulation of G9a is associated with sensitizing effects of sorafenib in HCC cells 25 3.8 Inducible shRNA-mediated knockdown of G9a sensitized HCC cells to sorafenib-induced cytotoxicity 25 3.9 G9a expression is closely associated with increased cell proliferation in sorafenib-resistant Huh7 (Huh7-SR) cells 26 3.10 miR-122 levels are significantly reduced in primary human HCCs and inversely correlated with expression of G9a in HCC cell lines 27 3.11 Identification of miR-122 as a negative regulator of G9a 27 3.12 Overexpression of miR-122 suppresses cell proliferation in HCC cells through induction of autophagy 28 3.13 Ectopic overexpression of miR-122 enhances the sensitivity of HCC cells to sorafenib 28 3.14 An inflammatory cytokine, Interleukin-6 (IL-6), induces G9a protein expression 29 Chapter 4. Discussion 31 References 38 Figures and figure legends 46 Appendix 86 | |
dc.language.iso | en | |
dc.title | 探討組蛋白甲基轉移酶G9a在肝癌進程中的角色 | zh_TW |
dc.title | Evaluation of the Role of Histone Methyltransferase G9a
in Hepatocellular Carcinoma Progression | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 鄭安理,王朝鐘(Chau-Jong Wang),蕭宏昇(Michael Hsiao),洪文俊(Wen-Chun Hung) | |
dc.subject.keyword | G9a,miR-122,細胞自噬,組蛋白修飾,肝癌, | zh_TW |
dc.subject.keyword | G9a,miR-122,autophagy,histone modifications,hepatocellular carcinoma (HCC), | en |
dc.relation.page | 86 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-07-26 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 毒理學研究所 | zh_TW |
顯示於系所單位: | 毒理學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 4.37 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。